CYTH2 and metabolic syndrome: As inhibition of ARNO impaired the phenotypic switch of VSMC, this GEF may become an interesting target when developing new strategies aiming at limiting the invasion of VSMC in the vasculature, such as in restenosis upon stenting or even atherosclerosis in patients prone to vascular inflammatory disease, such as diabetes or metabolic syndrome.